Press release
Lawsuit filed for Investors who lost money with shares of Geron Corporation (NASDAQ: GERN)
A lawsuit was filed on behalf of investors in Geron Corporation (NASDAQ: GERN) shares over alleged securities laws violations.
Investors who purchased shares of Geron Corporation (NASDAQ: GERN) have certain options and for certain investors are short and strict deadlines running. Deadline: May 12, 2025. NASDAQ: GERN investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
Foster City, CA based Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology.
On February 26, 2025, Geron Corporation (NASDAQ: GERN) announced its financial results for the fourth quarter of fiscal year 2024, disclosing that Rytelo's growth had flattened over the preceding months, attributing the diminished growth on seasonality, competition, lack of awareness for Rytelo, and the burden of the monitoring requirement necessary for the drug treatment.
Shares of Geron Corporation (NASDAQ: GERN) declined from $5.34 per share on June 12, 2024, to $1.65 per share on March 11, 2025.
The plaintiff claims that between June 7, 2024 and February 25, 2025, the defendants provided investors with material information concerning defendants' expectations for the launch and growth potential of Rytelo (imetelstat), and that the defendants' statements included, among other things, confidence in Geron's ability to capitalize on the purportedly significant unmet need for the drug and to execute on its commercial plan to target first-line ESA ineligible patients, while continually minimizing the risks associated with the burden of the weekly monitoring requirement for Rytelo and the impacts of seasonality and existing competition on the drug's sales.
Those who purchased shares of Geron Corporation (NASDAQ: GERN) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Lawsuit filed for Investors who lost money with shares of Geron Corporation (NASDAQ: GERN) here
News-ID: 3940405 • Views: …
More Releases from Shareholders Foundation, Inc.
Lawsuit filed for Investors who lost money with shares of West Pharmaceutical Se …
An investor, who purchased shares of West Pharmaceutical Services, Inc. (NYSE: WST), filed a lawsuit in the U.S. District Court for the Eastern District of Pennsylvania over alleged violations of Federal Securities Laws by West Pharmaceutical Services, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of West Pharmaceutical Services, Inc. (NYSE: WST) have certain options and for certain investors are short and strict deadlines running.…
enCore Energy Corp. (NASDAQ: EU) Long Term Investor Investigation of potential W …
An investigation on behalf of current long-term investors in shares of enCore Energy Corp. (NASDAQ: EU) concerning potential breaches of fiduciary duties by certain directors and officers of enCore Energy Corp. was announced.
Investors who are current long term investors in enCore Energy Corp. (NASDAQ: EU) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for…
Sana Biotechnology, Inc. (NASDAQ: SANA) Investor Alert: Deadline in Lawsuit on M …
A deadline is coming up on May 20, 2025 in the lawsuit filed for certain investors of Sana Biotechnology, Inc. (NASDAQ: SANA) over alleged securities laws violations by Sana Biotechnology, Inc.
Investors who purchased shares of Sana Biotechnology, Inc. (NASDAQ: SANA) have certain options and there are strict and short deadlines running. Deadline: May 20, 2025. Sana Biotechnology, Inc. (NASDAQ: SANA) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or…
Investors who hold shares of e.l.f. Beauty, Inc. (NYSE: ELF) Long Term should co …
An investigation was announced for long-term investors in shares of e.l.f. Beauty, Inc. (NYSE: ELF) concerning potential breaches of fiduciary duties by certain directors of e.l.f. Beauty, Inc.
Investors who are current long term investors in e.l.f. Beauty, Inc. (NYSE: ELF) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in…
More Releases for Geron
Stem Cell Umbilical Cord Blood Market to Show Incredible Growth by 2028 | Geron …
This comprehensive Stem Cell Umbilical Cord Blood market analysis sheds insight on the producers' position, which aids in keeping one's business on the go. The essential factors such as end-client market data, channel characteristics, and central members are among the main components to remember for this market study. It provides excellent market assessment and understanding, allowing central members to stay updated and maintain their position in a competitive market. The…
Embryonic Stem Cell Market to see Huge Growth by 2025 | BioTime, Caladrius Biosc …
Latest released the research study on Global Embryonic Stem Cell Market, offers a detailed overview of the factors influencing the global business scope. Embryonic Stem Cell Market research report shows the latest market insights, current situation analysis with upcoming trends and breakdown of the products and services. The report provides key statistics on the market status, size, share, growth factors of the Embryonic Stem Cell Market. The study covers emerging…
Stem Cells Industry Market has huge growth in industry 2020 : ViaCyte, Inc. , St …
Stem cell therapies possess significant potential in the treatment of various diseases and injuries. With several public and private organizations playing an active role in funding and encouraging stem cell-based research programs, the global stem cell therapy market is expected to grow at a significant pace during next decade. The stem cell therapy market comprises a range of stem cell-based products which are utilized for the treatment of various diseases…
Investigation for Long-Term Investors in shares of Geron Corporation (NASDAQ: GE …
An investigation was announced for current long-term investors in shares of Geron Corporation (NASDAQ: GERN) concerning potential breaches of fiduciary duties by certain directors and officers of Geron Corporation.
Investors who are current long term investors in Geron Corporation (NASDAQ: GERN) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in…
Deadline in Lawsuit for Investors in shares of Geron Corporation (NASDAQ: GERN) …
The Shareholders Foundation announced that a deadline is coming up on March 23, 2020 in the lawsuit filed for certain investors of Geron Corporation (NASDAQ: GERN) over alleged securities laws violations by Geron Corporation.
Investors who purchased shares of Geron Corporation (NASDAQ: GERN) have certain options and there are strict and short deadlines running. Deadline: March 23, 2020. NASDAQ: GERN stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858)…
Lawsuit filed for Investors in shares of Geron Corporation (NASDAQ: GERN)
An investor, who purchased shares of Geron Corporation (NASDAQ: GERN), filed a lawsuit over alleged violations of Federal Securities Laws by Geron Corporation.
Investors who purchased shares of Geron Corporation (NASDAQ: GERN) have certain options and for certain investors are short and strict deadlines running. Deadline: March 23, 2020. NASDAQ: GERN investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
Geron Corporation was developing imetelstat in partnership…
